Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.
Часто задаваемые вопросы
В каком секторе работает Catabasis Pharmaceuticals Inc (CATB)?
Catabasis Pharmaceuticals Inc относится к сектору Здравоохранение.
Выплачивает ли Catabasis Pharmaceuticals Inc (CATB) дивиденды?
Нет, Catabasis Pharmaceuticals Inc не выплачивает дивиденды.